Antiseptic efficacy of disinfecting solutions in suspension test in vitro against methicillin-resistant Staphylococcus aureus, Pseudomonas aeruginosa and Escherichia coli in pressure sore wounds after spinal cord injury.
In pressure sore wounds after spinal cord injury, methicillin-resistant Staphylococcus aureus can be detected in 2% of the cases. The elimination of the germ is the aim of the treatment. Pressure sore wounds are an often found complication after spinal cord injury. For local treatment five commercially available antiseptics for the skin and mucous membrane were tested in vitro. The method used is a modified qualitative and quantitative suspension test. The antiseptics were tested without and with addition of 5% albumin in order to simulate the conditions of the wound in vivo. The results show a superior efficacy of the povidone-iodine preparations. Betadine, probably due to the higher concentration, is more efficacious than Braunol; chlorhexidine is sufficiently efficacious without the addition of albumin. These results still have to be confirmed by in vivo studies.
Michel
D
D
Swiss Paraplegic Center, Nottwil, Switzerland.
Zäch
G A
GA
D000891:Anti-Infective Agents, Local / Q000008:administration & dosage / Q000627:therapeutic use*; D001645:Biguanides / Q000008:administration & dosage / Q000627:therapeutic use; D020843:Chamomile; D002710:Chlorhexidine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D004926:Escherichia coli / Q000187:drug effects*; D004927:Escherichia coli Infections / Q000188:drug therapy*; D005419:Flavonoids / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007097:Imines; D007466:Iodophors / Q000008:administration & dosage / Q000627:therapeutic use; D016106:Methicillin Resistance; D009822:Oils, Volatile / Q000008:administration & dosage / Q000627:therapeutic use; D010946:Plants, Medicinal; D011206:Povidone-Iodine / Q000008:administration & dosage / Q000627:therapeutic use; D003668:Pressure Ulcer / Q000188:drug therapy / Q000382:microbiology*; D011552:Pseudomonas Infections / Q000188:drug therapy*; D011550:Pseudomonas aeruginosa / Q000187:drug effects*; D011725:Pyridines / Q000008:administration & dosage / Q000627:therapeutic use; D000644:Quaternary Ammonium Compounds / Q000008:administration & dosage / Q000627:therapeutic use; D012709:Serum Albumin / Q000494:pharmacology; D012867:Skin / Q000382:microbiology; D013119:Spinal Cord Injuries / Q000150:complications*; D013203:Staphylococcal Infections / Q000188:drug therapy*; D013211:Staphylococcus aureus / Q000187:drug effects*
D000891:Anti-Infective Agents, Local; D001645:Biguanides; D005419:Flavonoids; D007097:Imines; D007466:Iodophors; D009822:Oils, Volatile; D011725:Pyridines; D000644:Quaternary Ammonium Compounds; D012709:Serum Albumin; C031233:polihexanide; D011206:Povidone-Iodine; C010882:chlorhexidine gluconate; C034213:octenidine; D002710:Chlorhexidine